Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Australia to continue AstraZeneca vaccination despite blood clotting case

WorldApr 03, 2021 02:30AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: Oxford/AstraZeneca's COVID-19 vaccine at a vaccination centre in Antwerp 2/2

By Lidia Kelly

MELBOURNE (Reuters) - Australia will continue its inoculation programme with AstraZeneca (NASDAQ:AZN) PLC, health officials said on Saturday, after a blood clotting case raised concern about the safety of the vaccine.

A 44-year-old man was admitted to a Melbourne hospital with clotting, days after receiving the AstraZeneca vaccine, suffering serious thrombosis, a condition that prevents normal blood flow though the circulatory system.

The Therapeutic Goods Administration (TGA) regulator and a panel, the Australian Technical Advisory Group on Immunisation (ATAGI), met late Friday and early Saturday to discuss further advice on the AstraZeneca vaccine.

"We have not been advised at this time by ATAGI or the TGA to pause the rollout of the AstraZeneca vaccine in Australia," Australia's deputy chief medical officer, Michael Kidd, told a televised briefing Saturday afternoon.

Kidd said, however, that the blood clotting case is "likely" related to the vaccine.

"The risks of serious side effects remain very low, but safety is paramount and that is why TAGI and the TGA are continuing to do due diligence on this case," Kidd said, adding that further announcements would come next week.

On Thursday, Britain identified 30 cases of rare blood clot events following use of the vaccine. Several nations, including Canada, France, Germany and Spain, limited its use after similar reports.

Possible complications with the rollout of the AstraZeneca vaccine could further slow the already delayed inoculation drive in Australia.

Australia launched mass vaccinations for its 25 million people in February, with most expected to receive the University of Oxford/AstraZeneca vaccine, as 50 million doses are being produced domestically by CSL (OTC:CSLLY) Ltd.

The country has had troubles, however, rolling out the programme, missing a March target by about 3.3 million doses as states and the federal government bickered over the blame.

The troubles follow a year of significant success curbing the virus, with snap lockdowns, border closures and swift tracking limiting coronavirus infections to just under 29,300 infections, with 909 COVID-19 deaths.

On Saturday, Queensland state, the epicentre of the most recent small outbreak of the coronavirus, recorded one new infection, health officials said, but risks to the public were minimal as the victim had been in isolation for days.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access)

(Interactive graphic tracking global spread of coronavirus: https://graphics.reuters.com/world-coronavirus-tracker-and-maps)

Australia to continue AstraZeneca vaccination despite blood clotting case
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email